Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
New tuberculosis study findings reported from S.G. Reed and co-authors
April 22nd, 2009
According to recent research from the United States, "The development of a vaccine for tuberculosis requires a combination of antigens and adjuvants capable of inducing appropriate and long-lasting T cell immunity. We evaluated Mtb72F formulated in AS02A in the cynomolgus monkey model." "The vaccine was immunogenic and caused no adverse reactions. When monkeys were immunized with bacillus Calmette-Guerin ( BCG) and then boosted with Mtb72F in AS02A, protection superior to that afforded by using BCG alone was achieved, as measured by clinical parameters, pathology, and survival. We observed long-term survival and evidence of reversal of disease progression in monkeys...
Source: Vaccine Weekly (2009-04-22)
|
